Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1400704

registered interest
date	07/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will add to the National Booking System covid-19 vaccination centres which have the capacity of 500 vaccinations a week but which are below the current 1,000 vaccinations per week threshold.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	99302
answer	answer is ministerial correction date of answer 02/03/2022 answer text <p>The criteria for adding new vaccination centres or sites to the National Booking System (NBS) is dependent upon the delivery model. All community pharmacy vaccination sites and mass vaccination centres are automatically added to the NBS regardless of their capacity. Regional systems prioritise the addition of sites to the NBS according to local need and may also include smaller sites such as ‘pop-ups’ to meet local care needs.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 02/03/2022 10:04:35 answering member 4447 label Biography information for Maggie Throup
tabling member	280 label Biography information for Michael Fabricant

1399371

registered interest
date	04/01/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to initiate a fourth mass covid-19 vaccination programme.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	96759
answer	answer is ministerial correction date of answer 10/01/2022 answer text <p>We have no current plans for a fourth mass COVID-19 vaccination programme.</p><p>The Joint Committee on Vaccination and Immunisation (JCVI) has stated that it is not known whether recurrent boosters will be required in the long term. The current advice on booster vaccinations applies to this highly active phase of the pandemic. We will continue to be informed by the latest scientific advice from the JCVI on whether further action is required.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 10/01/2022 17:55:09 answering member 4447 label Biography information for Maggie Throup
tabling member	280 label Biography information for Michael Fabricant

1399372

registered interest
date	04/01/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans there are to manipulate the covid-19 vaccine to sensitise it to the omicron and other variants; and when he estimates such vaccines might become available.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	96760
answer	answer is ministerial correction date of answer 12/01/2022 answer text <p>Recent analysis supports our understanding that the Pfizer/BioNTech and Moderna vaccines, which are currently being deployed in the UK, appear to work well against the current dominant variants of COVID-19 after a booster-dose. Continuing to administer these vaccines at scale remains essential in our path out of the pandemic.</p><p> </p><p>The Government continues to assess our existing vaccine portfolio against current variants, working closely with vaccine manufacturers and the UK Health Security Agency to understand the efficacy of our current vaccine portfolio against new variants.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/01/2022 09:49:01 answering member 4020 label Biography information for George Freeman
tabling member	280 label Biography information for Michael Fabricant

1356481

registered interest
date	17/09/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what plans his Department has to acquire vaccines to provide protection from the most recent variants of covid-19; and if he will make a statement.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	50943
answer	answer is ministerial correction date of answer 23/09/2021 answer text <p>We are planning for all scenarios in the fight against COVID-19 and the Vaccine Taskforce is taking a number of steps to ensure the UK is prepared to respond to current and emerging COVID-19 variants as quickly as possible.</p><p> </p><p>However, current data suggests that all deployed COVID-19 vaccines in the UK - AstraZeneca, Pfizer and Moderna - offer protection against the prevalent virus variants currently circulating in the UK, and recent data indicates that the Pfizer vaccine remains effective against Beta variant.</p><p> </p><p>We continue to assess the efficacy of the vaccines currently in our portfolio against new and future variants of the virus and continue to work closely with vaccine manufacturers to ensure that vaccines that have already received UK regulatory approval could be suitably updated, where possible and where needed, to remain effective against emerging variants of SARS-CoV-2.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 23/09/2021 16:43:51 answering member 4020 label Biography information for George Freeman
tabling member	280 label Biography information for Michael Fabricant

1348830

registered interest
date	20/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the proposed autumn Covid-19 booster vaccination programme will include a modified vaccine with improved efficacy against the (a) delta and (b) other covid-19 variants.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	36517
answer	answer is ministerial correction date of answer 06/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) interim advice on a potential COVID-19 booster vaccination programme states that vaccines designed specifically against variants of concern will not be available in time for booster revaccination this autumn. The use of variant vaccines will be considered by the JCVI in due course.</p><p>Final decisions on the timing, scope and cohort eligibility of any COVID-19 vaccine booster programme will be confirmed once the JCVI has provided their final advice. The JCVI’s advice will take into account the latest epidemiological situation, additional scientific data from trials such as COV-Boost, surveillance of the effectiveness of the vaccines over time and emerging variants.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 06/09/2021 11:33:35 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	280 label Biography information for Michael Fabricant

1329404

registered interest
date	04/06/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether advanced orders placed for new covid-19 vaccines such as the Janseen vaccine will be designed around the latest variants known to be in existence at the time of delivery.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	10158
answer	answer is ministerial correction date of answer 14/06/2021 answer text <p>The UK Government has secured early access to 397 million vaccines doses through supply agreements with six separate vaccine developers. This includes agreements with:</p><p> </p><ul><li>Pfizer/BioNTech for 100 million doses</li><li>University of Oxford/AstraZeneca for 100 million doses</li><li>Moderna for 17 million doses</li><li>Novavax for 60 million doses</li><li>Janssen for 20 million doses</li><li>Valneva for 100 million doses</li></ul><p> </p><p>In addition, the Government has a reservation agreement with GlaxoSmithKline/Sanofi Pasteur for 60 million doses and a non-binding agreement with CureVac for 50 million doses.</p><p> </p><p>The Government is working closely with vaccine manufacturers and Public Health England to understand the efficacy of our current vaccine portfolio against new variants and will continue to monitor the picture with variants as it develops. <br> <br> The Government announced on 3 June 2021 that it has started commercial negotiations with AstraZeneca for future supplies of the University of Oxford/AstraZeneca vaccine that have been adapted to tackle the Beta variant first identified in South Africa.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 14/06/2021 15:23:17 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	280 label Biography information for Michael Fabricant

1299369

registered interest
date	03/03/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, further to the Answer of 3 March to Question 154738, what support his Department is providing for (a) research on and (b) trials of vaccines offering immunity to covid-19 which can be delivered by gradual absorption through the skin using an adhesive patch.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	162509
answer	answer is ministerial correction date of answer 15/03/2021 answer text <p>The Department has not currently commissioned any research into COVID-19 vaccines which can be delivered through an adhesive patch but the National Institute for Health Research, as the biggest public funder of health research in the United Kingdom, continues to welcome funding applications for research into any aspect of human health, including on COVID-19 vaccine related research.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 15/03/2021 13:23:04 answering member 4362 label Biography information for Edward Argar
tabling member	280 label Biography information for Michael Fabricant

1287103

registered interest
date	19/02/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what support his Department is providing for (a) research on and (b) trials of oral vaccines offering immunity to covid-19.
tabling member constituency	Lichfield
tabling member printed	Michael Fabricant
uin	154738
answer	answer is ministerial correction date of answer 03/03/2021 answer text <p>Through a joint rolling research call for COVID-19 research between the National Institute for Health Research and UK Research and Innovation, funding of over £500,000 has been committed to a study looking at the safety and immunogenicity of two candidate COVID-19 vaccines administered to the respiratory tract in aerosol form, with an expected end date in August 2021.</p><p>In addition, Innovate UK, have been managing the delivery of £75 million of the £110 million Department-funded UK Vaccine Network programme. Nine Departmental projects within this portfolio were repurposed to identify other COVID-19 vaccines solutions. Also, two Innovate UK grants worth over £2.2 million in total, were awarded to Stabilitech, now known as IosBio, to assess its COVD-19 vaccine candidate that has an oral capsule delivery system in animal efficacy studies. This technology is now being tested in participants in clinical trials in South Africa and the United States.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 03/03/2021 16:21:42 answering member 4362 label Biography information for Edward Argar
tabling member	280 label Biography information for Michael Fabricant